Doxorubicin-Poly-l-lysine Peptide Polymers: A Rapid, Selective, and Biocompatible Therapeutic for Infection and Cancer Prevention
Source abstract
Abstract
The intricate relationship between infection and cancer, particularly the heightened susceptibility to infection in patients with compromised immune systems due to the toxicity of conventional chemotherapy, poses significant challenges, such as prolonging recovery and escalating financial burdens. Therefore, integrating antimicrobial activity while concurrently enhancing biocompatibility is crucial for advancing traditional anticancer agents. In this study, we developed a series of biocompatible peptide polymers with dual antimicrobial and anticancer functions through a facile, drug-initiated polymerization approach. These peptide polymers demonstrated rapid action and greater selectivity for tumor cells and Gram-positive pathogens over normal cells compared with free doxorubicin. Multiple mechanisms, including membrane disruption, induction of cell necrosis, and nuclear-dominated intracellular distribution, were revealed for the peptide polymers. These results collectively suggest a low propensity for inducing drug resistance. Overall, these peptide polymers combine the merits of conventional anticancer agents and antimicrobial peptide mimics, offering a promising strategy for anticancer drug development and clinical oncology applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Biopolymer Synthesis and Applications · Antimicrobial Peptides and Activities · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Material Science and Engineering, Tongji University, 4800 Caoan Road, Shanghai 201804, China
Translational Medical Center for Stem Cell Therapy, Department of Dermatology, Tongji Hospital, School of Medicine, Tongji University, 500 Zhennan Road, Shanghai 200331, China
Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, 639 Zhizaoju Road, Shanghai 200023, China
Funding
National Natural Science Foundation of China
References (48)
Show source-provided references
1. 10.3322/caac.2183410.3322/caac.21834 ↗
2. 10.1001/jamadermatol.2022.016010.1001/jamadermatol.2022.0160 ↗
3. 10.1001/jamaoncol.2022.782610.1001/jamaoncol.2022.7826 ↗
4. 10.1016/j.cellin.2023.10012510.1016/j.cellin.2023.100125 ↗
5. 10.1158/1940-6207.CAPR-22-051110.1158/1940-6207.CAPR-22-0511 ↗
6. 10.3390/ijms2404311010.3390/ijms24043110 ↗
7. 10.1007/978-3-319-04220-6_210.1007/978-3-319-04220-6_2 ↗
8. 10.1007/s12094-021-02690-x10.1007/s12094-021-02690-x ↗
9. 10.4103/0973-1482.13926710.4103/0973-1482.139267 ↗
10. 10.1128/AAC.28.3.43710.1128/AAC.28.3.437 ↗
11. 10.1002/cpt.300210.1002/cpt.3002 ↗
12. 10.1111/lam.1321310.1111/lam.13213 ↗
13. 10.1021/acs.langmuir.3c0023510.1021/acs.langmuir.3c00235 ↗
14. 10.1080/25740881.2020.178422210.1080/25740881.2020.1784222 ↗
15. 10.1016/j.bioorg.2021.10547010.1016/j.bioorg.2021.105470 ↗
16. 10.1007/s13346-023-01323-w10.1007/s13346-023-01323-w ↗
17. 10.1016/j.actbio.2022.02.03310.1016/j.actbio.2022.02.033 ↗
18. 10.1016/j.jconrel.2023.08.01910.1016/j.jconrel.2023.08.019 ↗
19. 10.3389/fchem.2021.65930410.3389/fchem.2021.659304 ↗
20. 10.3389/fbioe.2021.74465710.3389/fbioe.2021.744657 ↗
21. 10.1007/s10118-022-2859-110.1007/s10118-022-2859-1 ↗
22. 10.1038/s41598-021-88791-710.1038/s41598-021-88791-7 ↗
23. 10.1002/jgm.107510.1002/jgm.1075 ↗
24. 10.1007/s10118-015-1632-010.1007/s10118-015-1632-0 ↗
25. 10.1080/1040841X.2023.218621510.1080/1040841X.2023.2186215 ↗
26. 10.1021/nn305860k10.1021/nn305860k ↗
27. 10.1021/jm400647r10.1021/jm400647r ↗
28. 10.1021/acs.bioconjchem.9b0075510.1021/acs.bioconjchem.9b00755 ↗
29. 10.1021/bc400326y10.1021/bc400326y ↗
30. 10.1016/j.jconrel.2018.01.03310.1016/j.jconrel.2018.01.033 ↗
31. 10.1016/j.jconrel.2020.07.03010.1016/j.jconrel.2020.07.030 ↗
32. 10.1021/acs.jafc.9b0752410.1021/acs.jafc.9b07524 ↗
33. 10.1016/j.eurpolymj.2018.07.01710.1016/j.eurpolymj.2018.07.017 ↗
34. 10.1021/acsami.8b0791710.1021/acsami.8b07917 ↗
35. 10.1021/acsmacrolett.4c0018710.1021/acsmacrolett.4c00187 ↗
36. 10.1021/acs.molpharmaceut.4c0045010.1021/acs.molpharmaceut.4c00450 ↗
37. 10.1042/bj2015046710.1042/bj20150467 ↗
38. 10.1016/j.tox.2010.03.01210.1016/j.tox.2010.03.012 ↗
39. 10.1021/acsabm.1c0113210.1021/acsabm.1c01132 ↗
40. 10.1126/sciadv.adp660410.1126/sciadv.adp6604 ↗
41. 10.3390/ijms22211140110.3390/ijms222111401 ↗
42. 10.3390/polym1001009310.3390/polym10010093 ↗
43. 10.1016/j.molmed.2014.02.00710.1016/j.molmed.2014.02.007 ↗
44. 10.1134/S106816202205004110.1134/S1068162022050041 ↗
45. 10.1016/S0022-1759(00)00233-710.1016/S0022-1759(00)00233-7 ↗
46. 10.1038/s41467-020-14928-310.1038/s41467-020-14928-3 ↗
47. 10.1016/j.tips.2017.01.00310.1016/j.tips.2017.01.003 ↗
48. 10.1097/FPC.0b013e32833ffb5610.1097/FPC.0b013e32833ffb56 ↗